Conference Calls, New Appointments, Agreements, Pricing of Offerings and New Clinical Trials - Research Report on Abbott,

 Conference Calls, New Appointments, Agreements, Pricing of Offerings and New
  Clinical Trials - Research Report on Abbott, Cubist, Pacific Biosciences,
                          Synageva, and Oncothyreon

PR Newswire

NEW YORK, September 30, 2013

NEW YORK, September 30, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Abbott
Laboratories (NYSE: ABT), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Pacific
Biosciences of California (NASDAQ: PACB), Synageva BioPharma Corp. (NASDAQ:
GEVA), and Oncothyreon Inc. (NASDAQ: ONTY). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Abbott Laboratories Research Report

On September 25, 2013, Abbott Laboratories (Abbott) announced that it will
release its Q3 2013 financial results on Wednesday, October 16, 2013, before
the market opens. The Company informed that following the results release, it
will also host an earnings conference call at 8:00 a.m. CT (9:00 a.m. ET)
which will be webcast live through Abbott's Investor Relations website. In
another announcement dated July 17, 2013, Abbott confirmed its guidance for
full-year 2013 as it anticipates EPS to be within $1.98 to $2.04, in addition
the Company expects full-year 2013 EPS from continuing operations to range
from $1.39 to $1.45, including net specified items of approximately $0.59 per
share. The Full Research Report on Abbott Laboratories - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-09-25/ABT]

Cubist Pharmaceuticals Inc. Research Report

On September 25, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced that
Kenneth J. Martin has been appointed to the Company's Board of Directors.
According to the Company, since 2007, Mr. Martin has been serving as a member
of the Board of WABCO Holdings, Inc. Ken Bate, Non-Executive Chairman of the
Board of Directors of Cubist, said, "Ken Martin has an exceptional mix of
global finance, industry and leadership expertise that will be a valued asset
to Cubist, and we are thrilled to have him join our Board. Importantly, Ken's
experience at Wyeth gives him an important perspective as Cubist begins its
next, exciting chapter focused on global growth and continuing to drive
significant shareholder value." The Full Research Report on Cubist
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-25/CBST]

Pacific Biosciences of California Research Report

On September 25, 2013, Pacific Biosciences of California (Pacific Biosciences)
announced that it has entered into an agreement with Roche Diagnostics (Roche)
to develop diagnostic products, including sequencing systems and consumables,
based on Pacific Biosciences' Single Molecule, Real-Time (SMRT) technology.
The Company informed that as per the agreement, Pacific Biosciences will
develop and manufacture certain products for clinical use, which it will sell
exclusively to Roche, who has worldwide rights to exclusively distribute these
products in the field of human in vitro diagnostics. Pacific Biosciences
further added that it will continue to market its current and future products
for all fields outside of human in vitro diagnostics, including research,
plant, animal, and applied markets. Dan Zabrowski, Head of the Sequencing Unit
at Roche said, "We see great potential in Pacific Biosciences' sequencing
technology for the development of future clinical sequencing applications.
Sequencing will be a key technology in addressing the strong and growing
demand for genetic and genomic solutions in the clinic. We are looking forward
to this partnership to accelerate and support the transition of DNA sequencing
into routine diagnostics through our joint development efforts."The Full
Research Report on Pacific Biosciences of California - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-09-25/PACB]

Synageva BioPharma Corp. Research Report

On September 24, 2013, Synageva BioPharma Corp. (Synageva) announced the
pricing of its previously announced underwritten public offering of common
stock comprising of 2.75 million shares at a price of $56.63 per share. The
Company stated in relation to this offering Synageva has granted to the
underwriters a 30-day option to purchase 412,500 additional shares of common
stock, which if exercised, will bring the total shares of its common stock
offering to approximately 3.16 million shares. The Full Research Report on
Synageva BioPharma Corp. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-25/GEVA]

Oncothyreon Inc. Research Report

On September 25, 2013, Oncothyreon Inc. (Oncothyreon) announced that the
biopharmaceutical division of Merck KGaA, Merck Serono has decided to continue
clinical development of the investigational MUC1 antigen-specific cancer
immunotherapy tecemotide (L-BLP25, formerly known as Stimuvax). According to
the Company, Merck Serono is currently developing tecemotide under a license
agreement with Oncothyreon and will conduct a Phase 3 trial called START2 for
patients with unresectable, locally advanced, Stage III non-small cell lung
cancer (NSCLC), based on the outcome of the prior START trial.Dr. Annalisa
Jenkins, Head of Global Drug Development and Medical for Merck Serono, said,
"The START data delivered important insights that we believe justify further
investigation in a new Phase 3 program. NSCLC is a devastating disease, and we
are pleased to be able to continue supporting innovation in this important
emerging field of immuno-oncology." The Full Research Report on Oncothyreon
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-25/ONTY]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by NamrataMaheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.InvestorsReports.com

SOURCE Investors' Reports

Contact: Media Contact: Kristi Saunders, +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.